- Home
- PRPO vs NLSP Comparison
PRPO vs NLSP Comparison
Compare PRPO & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- NLSP
- Stock Information
- Founded
- PRPO N/A
- NLSP 2015
- Country
- PRPO United States
- NLSP Switzerland
- Employees
- PRPO N/A
- NLSP N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- NLSP Health Care
- Exchange
- PRPO Nasdaq
- NLSP Nasdaq
- Market Cap
- PRPO 22.0M
- NLSP 12.4M
- IPO Year
- PRPO N/A
- NLSP 2021
- Fundamental
- Price
- PRPO $17.55
- NLSP $2.03
- Analyst Decision
- PRPO
- NLSP
- Analyst Count
- PRPO 0
- NLSP 0
- Target Price
- PRPO N/A
- NLSP N/A
- AVG Volume (30 Days)
- PRPO 16.8K
- NLSP 193.3K
- Earning Date
- PRPO 11-05-2025
- NLSP 10-17-2025
- Dividend Yield
- PRPO N/A
- NLSP N/A
- EPS Growth
- PRPO N/A
- NLSP N/A
- EPS
- PRPO N/A
- NLSP N/A
- Revenue
- PRPO $21,242,000.00
- NLSP N/A
- Revenue This Year
- PRPO N/A
- NLSP N/A
- Revenue Next Year
- PRPO N/A
- NLSP N/A
- P/E Ratio
- PRPO N/A
- NLSP N/A
- Revenue Growth
- PRPO 27.05
- NLSP N/A
- 52 Week Low
- PRPO $3.90
- NLSP $1.30
- 52 Week High
- PRPO $22.38
- NLSP $6.97
- Technical
- Relative Strength Index (RSI)
- PRPO 53.87
- NLSP 43.44
- Support Level
- PRPO $19.40
- NLSP $1.88
- Resistance Level
- PRPO $22.38
- NLSP $2.29
- Average True Range (ATR)
- PRPO 1.39
- NLSP 0.12
- MACD
- PRPO -0.01
- NLSP -0.01
- Stochastic Oscillator
- PRPO 40.33
- NLSP 36.59
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.